Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider Sells $382,994.46 in Stock

by · The Cerbat Gem

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) insider David Malcom Rodman sold 25,482 shares of Mineralys Therapeutics stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $15.03, for a total value of $382,994.46. Following the completion of the transaction, the insider now owns 135,974 shares in the company, valued at $2,043,689.22. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Mineralys Therapeutics Stock Performance

Shares of MLYS stock traded down $0.12 during trading hours on Friday, reaching $14.04. The company had a trading volume of 329,357 shares, compared to its average volume of 177,844. The company has a market capitalization of $698.21 million, a P/E ratio of -5.23 and a beta of 1.71. Mineralys Therapeutics, Inc. has a twelve month low of $5.85 and a twelve month high of $16.91. The stock’s fifty day simple moving average is $12.87 and its 200 day simple moving average is $12.58.

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). During the same quarter last year, the business posted ($0.31) EPS. As a group, equities analysts expect that Mineralys Therapeutics, Inc. will post -3.08 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Mineralys Therapeutics by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 982,932 shares of the company’s stock valued at $12,690,000 after acquiring an additional 4,952 shares in the last quarter. SR One Capital Management LP lifted its stake in shares of Mineralys Therapeutics by 12.4% in the first quarter. SR One Capital Management LP now owns 2,016,822 shares of the company’s stock worth $26,037,000 after buying an additional 222,222 shares during the last quarter. Affinity Asset Advisors LLC bought a new stake in Mineralys Therapeutics during the first quarter valued at about $4,234,000. Bellevue Group AG bought a new position in Mineralys Therapeutics in the 1st quarter worth approximately $119,000. Finally, RA Capital Management L.P. raised its stake in Mineralys Therapeutics by 52.6% during the 1st quarter. RA Capital Management L.P. now owns 4,850,984 shares of the company’s stock valued at $62,626,000 after purchasing an additional 1,672,508 shares during the last quarter. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Mineralys Therapeutics in a research report on Thursday, October 31st.

View Our Latest Analysis on MLYS

Mineralys Therapeutics Company Profile

(Get Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.

Featured Stories